Literature DB >> 33495156

Severe ulcerative oesophagitis caused by primary Epstein-Barr virus infection in an immunocompetent individual.

Ruben Due Lorentsen1, Louise Laurberg Klarskov2, Casper Steenholdt3.   

Abstract

Epstein-Barr virus (EBV) infects the vast majority of the human population. The primary infection in immunocompetent individuals is typically asymptomatic or presenting as infectious mononucleosis. Here, an 18-year-old man without medical history was admitted with mild non-specific symptoms of infection presenting primarily with severe dysphagia and epigastric pain. Gastroscopy revealed severe, extensive, ulcerative oesophagitis with suspicion of Crohn's disease. However, a diagnosis of primary EBV infection presenting as severe ulcerative oesophagitis and without systemic symptoms of infectious mononucleosis was made based on dynamic changes in EBV serology (shift from IgM to IgG positivity), EBV-specific immunohistochemical staining, and PCR analysis of biopsy specimens. This rare manifestation of primary EBV in an immunocompetent patient was treated symptomatically and resolved within a few weeks, and should be considered a differential diagnosis at otherwise unexplained ulcerative oesophagitis in younger individuals. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical decision making; endoscopy; erosive oesophagitis; infectious disease

Year:  2021        PMID: 33495156      PMCID: PMC7839876          DOI: 10.1136/bmjgast-2020-000586

Source DB:  PubMed          Journal:  BMJ Open Gastroenterol        ISSN: 2054-4774


Introduction

Epstein-Barr virus (EBV) infects >90% of the human population worldwide and with a variety of manifestations, notably infectious mononucleosis characterised by fever, lymphadenopathy, pharyngitis, hepatomegaly, and/or splenomegaly.1 After the primary infection, EBV is present lifelong as latent infection in B lymphocytes, but reactivation is rare—and if so typically due to immune impairment.1 Reactivation of EBV is a known, but rare, cause of infectious oesophagitis in immunosuppressed patients.2 3 In immunocompetent patients, however, primary EBV oesophagitis has only anecdotally been described.

Clinical case description

An 18-year-old male patient with no medical history or sexual risk behaviour, non-smoker and not drinking alcohol was admitted to our hospital due to fever up to 39.4°C, muscle pain, heartburn, epigastric pain, dysphagia, and odynophagia. The fever had appeared 4 days prior to admission, while the upper gastrointestinal symptoms started on the day before admission. The clinical examination revealed a fit and slender young man, temperature 37.6°C, pulse 100, blood pressure 106/77 mm Hg, and with worsening of epigastric tenderness and heartburn at palpation of the epigastrium. The examination was otherwise normal and with no signs of pharyngitis, lymphadenopathy, hepatomegaly, or splenomegaly. Laboratory testings revealed normal complete blood counts including normal leucocytes and neutrophils, increased C-reactive protein of 49 mg/L, and normal liver biochemistry apart from a slightly increased international normalised ratio (INR) of 1.4. Gastroscopy performed on the following day revealed multiple, centimetre-long, linear and circular ulcerations of various depth of the entire length of the oesophagus (figure 1a). The stomach and duodenum had normal endoscopic appearances. Biopsies from the oesophageal mucosa presented with fragments of well-differentiated squamous epithelium with only few intraepithelial inflammatory cells and the biopsies were dominated by deep ulcerations (figure 1b). Granulomas were not present. There were no morphological signs indicating viral infection, and fungal stainings were negative. The conclusion was unspecific ulcerations. Routine biopsies from the stomach and duodenum were normal. Symptomatic therapy with proton-pump inhibitor (pantoprazole) and mild analgesics (acetaminophen) was initiated. This was followed by rapid symptom improvement and the patient was discharged for further diagnostic workup in the outpatient clinic.
Figure 1

Endoscopic image of the oesophagus revealing multiple, linear and circular, centimetre-long ulcerations of varying depths involving the entire length of the oesophagus (A). Representative biopsy (H&E) from the oesophageal mucosa (B) presenting with ulcerated surface and granulation tissue, but without granulomas or morphological signs of fungi or viral infection. Immunohistochemical staining for Epstein-Barr virus (EBV) (C) revealing several positive cells (brown) and with subsequent PCR analysis confirming presence of EBV with a quantitative detection of 13 virus particles/µL.

Endoscopic image of the oesophagus revealing multiple, linear and circular, centimetre-long ulcerations of varying depths involving the entire length of the oesophagus (A). Representative biopsy (H&E) from the oesophageal mucosa (B) presenting with ulcerated surface and granulation tissue, but without granulomas or morphological signs of fungi or viral infection. Immunohistochemical staining for Epstein-Barr virus (EBV) (C) revealing several positive cells (brown) and with subsequent PCR analysis confirming presence of EBV with a quantitative detection of 13 virus particles/µL. At follow-up 2 weeks after discharge, the patient was feeling well and with normal routine laboratory tests including normalisation of INR. He described that the symptoms of heartburn and epigastric pain had rapidly subsided following discharge with a total symptom duration of 8 days after which he had stopped taking any medicine. Due to a faecal calprotectin level of 285 µg/g, MRI was carried out to rule out Crohn’s disease, and revealing normal appearance of the small and large bowel. The patient declined repeat gastroscopy or colonoscopy because he was feeling well. Virus serology detected borderline-positive EBV viral capsid antibodies (VCA) IgM, positive EBV VCA IgG, and positive nuclear antibodies (EBV nuclear antigen; EBNA) IgG. Cytomegalovirus (CMV) and varicella-zoster virus were IgG positive and IgM negative, and testings for herpes simplex virus (HSV) and HIV were negative. Thus, serological testings raised suspicion of primary infection with EBV as underlying cause. The biopsies were re-evaluated and found to be positive for EBV by specific EBV immunohistochemical staining (figure 1c). PCR confirmed infection with EBV with a quantitative detection of 13 virus particles/µL. Immunohistochemical stainings for CMV and HSV were negative. Repeat serology 5 months after discharge showed similar results including borderline-positive EBV VCA IgM and positive EBV VCA IgG and EBNA IgG. However, complete seroconversion had occurred at retesting 9 months after presentation with negative EBV VCA IgM and positive EBV VCA IgG and EBNA IgG, thus confirming that the underlying cause of severe ulcerative oesophagitis had been primary EBV infection.

Discussion

We report an extremely rare case of EBV oesophagitis caused by primary EBV infection in an otherwise healthy 18-year-old man presenting with mild, non-specific systemic symptoms of infection, but primarily with severe dysphagia, heartburn, and epigastric pain. EBV oesophagitis rarely occurs due to reactivation in immunocompromised patients, but has only anecdotally been observed as manifestation of the primary infection among immunocompetent individuals (table 1).4–6 The three previously reported cases all presented with non-specific symptoms of severe oesophagitis; non-specific, relatively long and deep, circular and linear ulcerations at endoscopy; and without specific histological findings by use of standard stainings. Thus, EBV oesophagitis can neither be detected by clinical presentation, endoscopic appearance, nor by routine evaluation of biopsies. Here, we unambiguously established the diagnosis due to typical dynamic changes in EBV serology, positive EBV-specific immunohistochemical staining, and by use of PCR analysis of biopsy specimens. Of note, two previous cases found false-negative serology and histology, with diagnosis based only on PCR; and another based the diagnosis solely on a positive Monospot test (table 1).5 6
Table 1

Reported cases of Epstein-Barr virus oesophagitis among immunocompetent patients

Gender and ageSymptomsEndoscopic findingsDiagnosisTreatment
Male, 23 years4Fever, diaphoresis, lethargy, weight loss, odynophagia, haematemesis, lymphadenopathyMultiple ulcerationsPositive Monospot testSymptomatic
Female, 27 years5Dysphagia, odynophagiaMultiple, well-circumscribed ulcerations, differing depthsPCR analysis of biopsyAciclovir
Male, 48 years6Fever, nausea, dysphagiaDenuded, extensive ulcerationsPCR analysis of biopsyAciclovir
Reported cases of Epstein-Barr virus oesophagitis among immunocompetent patients Notable differential diagnoses include infectious oesophagitis caused by other pathogens such as CMV or HSV, gastro-oesophageal reflux disease (GORD), and Crohn’s disease. We ruled out other potential infectious pathogens by serology and immunohistochemical stainings. GORD was considered unlikely due to the clinical presentation including rapid symptom evolvement with signs of systemic infection along with endoscopic findings not being classic for GORD. Crohn’s disease presenting with inflammatory activity confined only to the oesophagus and without any other gastrointestinal symptoms is rare.7 Endoscopic findings of Crohn’s disease are heterogeneous and include oedema and reddening, aphtas, ulcers, cobblestone appearance, stenosis, and potentially fistulas. Typical histological findings are fissurating ulcers, acute and chronic inflammatory infiltrates and sometimes non-caseating granulomas.7 Thus, although the endoscopic presentation and unspecific histology in this case could, in principle, have represented Crohn’s disease, this was ruled out by the detection of EBV in the biopsy specimen and a positive serology combined with a normal bowel MRI. Antiviral treatment of EBV oesophagitis was commenced in two out of three previous reported cases (table 1). However, any benefits from this treatment approach are highly unlikely given lack of effective antiviral therapy for EBV, as detailed in the references.8 9 We successfully treated our patient symptomatically and this approach resulted in rapid symptom relief likely due to the condition in this particular patient being relatively mild and self-limiting. In cases of more severe or chronic active EBV infection, corticosteroids and ciclosporin may be commenced.10 In conclusion, primary EBV infection presenting as severe ulcerative oesophagitis in healthy immunocompetent individuals is extremely rare but should be remembered as a differential diagnosis especially if suspicion of infectious oesophagitis or Crohn’s disease is raised combined with non-specific endoscopic findings of long and deep, circular or linear ulcerations. Suspicion would thus lead to earlier diagnosis with appropriate serological and histological investigations for EBV. Careful examinations to rule out concomitant causes for immunosuppression are also recommended. This diagnosis can be very challenging and should rely on collective evaluations of serology, as well as immunohistochemical stainings and PCR analysis of biopsies. The condition has a favourable prognosis and most cases can be treated symptomatically.
  10 in total

Review 1.  Epstein-Barr virus infection.

Authors:  J I Cohen
Journal:  N Engl J Med       Date:  2000-08-17       Impact factor: 91.245

2.  Fulminant Epstein-Barr virus esophagitis in an immunocompetent patient.

Authors:  A Annaházi; G Terhes; J Deák; L Tiszlavicz; A Rosztóczy; T Wittmann; R Róka
Journal:  Endoscopy       Date:  2011-10-21       Impact factor: 10.093

3.  A case of viral esophagitis.

Authors:  K S Tilbe; D A Lloyd
Journal:  J Clin Gastroenterol       Date:  1986-08       Impact factor: 3.062

4.  Epstein-Barr virus associated oesophageal ulcers in AIDS.

Authors:  V S Kitchen; M Helbert; N D Francis; R P Logan; F A Lewis; A W Boylston; A J Pinching; J R Harris
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

Review 5.  Antiviral agents for infectious mononucleosis (glandular fever).

Authors:  Muireann De Paor; Kirsty O'Brien; Tom Fahey; Susan M Smith
Journal:  Cochrane Database Syst Rev       Date:  2016-12-08

6.  Optimal treatment for chronic active Epstein-Barr virus disease.

Authors:  Jeffrey I Cohen
Journal:  Pediatr Transplant       Date:  2009-06

Review 7.  Infections of the esophagus: an update on risk factors, diagnosis, and management.

Authors:  P Hoversten; A K Kamboj; D A Katzka
Journal:  Dis Esophagus       Date:  2018-12-01       Impact factor: 3.429

8.  Evaluation and Management of Infectious Esophagitis in Immunocompromised and Immunocompetent Individuals.

Authors:  Nitin K Ahuja; John O Clarke
Journal:  Curr Treat Options Gastroenterol       Date:  2016-03

Review 9.  Crohn's disease of esophagus, stomach and duodenum.

Authors:  Andréa Maia Pimentel; Raquel Rocha; Genoile Oliveira Santana
Journal:  World J Gastrointest Pharmacol Ther       Date:  2019-03-07

10.  Unusual Epstein-Barr esophageal infection in an immunocompetent patient: a case report.

Authors:  Magdalini Pape; Kalliopi Mandraveli; Ioannis Sidiropoulos; Dimitrios Koliouskas; Stella Alexiou-Daniel; Filanthi Frantzidou
Journal:  J Med Case Rep       Date:  2009-06-29
  10 in total
  2 in total

1.  Epidemiology of the Epstein-Barr Virus in Autoimmune Inflammatory Rheumatic Diseases in Northern Brazil.

Authors:  Samires Avelino de Souza França; Julimar Benedita Gomes de Oliveira Viana; Hilda Carla Azevedo Góes; Ricardo Roberto de Souza Fonseca; Rogério Valois Laurentino; Igor Brasil Costa; Aldemir Branco Oliveira-Filho; Luiz Fernando Almeida Machado
Journal:  Viruses       Date:  2022-03-27       Impact factor: 5.818

2.  Primary Epstein-Barr Virus-Positive Mucocutaneous Ulcer of Esophagus: A Rare Case Report.

Authors:  Chunping Sun; Qingya Wang; Yujun Dong; Lin Nong; Yunlong Cai; Lihong Wang; Yuhua Sun; Wensheng Wang; Xinmin Liu
Journal:  J Clin Med       Date:  2022-08-21       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.